Adam Waxman

2.6k total citations
32 papers, 935 citations indexed

About

Adam Waxman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Adam Waxman has authored 32 papers receiving a total of 935 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 16 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Adam Waxman's work include Multiple Myeloma Research and Treatments (18 papers), CAR-T cell therapy research (7 papers) and Protein Degradation and Inhibitors (5 papers). Adam Waxman is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), CAR-T cell therapy research (7 papers) and Protein Degradation and Inhibitors (5 papers). Adam Waxman collaborates with scholars based in United States, Sweden and Belgium. Adam Waxman's co-authors include Brendan M. Weiss, Ola Landgren, Adam D. Cohen, Dan T. Vogl, Edward A. Stadtmauer, Alfred L. Garfall, Pamela J. Mink, William F. Anderson, Sigurður Y. Kristinsson and Susan S. Devesa and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Adam Waxman

31 papers receiving 924 citations

Peers

Countries citing papers authored by Adam Waxman

Since Specialization

Citations

This map shows the geographic impact of Adam Waxman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Waxman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Waxman more than expected).

Fields of papers citing papers by Adam Waxman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Waxman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Waxman. The network helps show where Adam Waxman may publish in the future.

Co-authorship network of co-authors of Adam Waxman

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Waxman. A scholar is included among the top collaborators of Adam Waxman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Waxman. Adam Waxman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma 2025 ·Blood Advances ·(unknown), Harper Hubbeling, Kang Yu, (unknown), Michael J. LaRiviere, John P. Plastaras, Adam D. Cohen, (unknown), Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Alfred L. Garfall, Sandra P. Susanibar-Adaniya	0
2	Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma 2024 ·Bone Marrow Transplantation ·(unknown), (unknown), Jonathan Sussman, Alfred L. Garfall, Adam D. Cohen, (unknown), Sandra P. Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer	2
3	Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis 2024 ·European Journal Of Haematology ·Margaret Stalker, Alfred L. Garfall, (unknown), Dan T. Vogl, Mia Djulbegovic, Sandra P. Susanibar-Adaniya, Edward A. Stadtmauer, (unknown), Adam Waxman	3
4	Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice 2024 ·JCI Insight ·Zainul S. Hasanali, Alfred L. Garfall, Lisa Burzenski, Leonard D. Shultz, Yan Tang, (unknown), Neil C. Sheppard, Wei Liu, (unknown), Dan T. Vogl, Adam D. Cohen, Adam Waxman, Sandra P. Susanibar-Adaniya, Martin Carroll, Edward A. Stadtmauer, David Allman	3
5	Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma 2024 ·Blood ·Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Nguyễn Văn Vĩnh Châu, (unknown), (unknown), Eva Bondesson, Helén Tuvesson, (unknown), Adam D. Cohen, Sandra P. Susanibar-Adaniya, Adam Waxman, (unknown), Alfred L. Garfall, Edward A. Stadtmauer	1
6	A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma 2023 ·Blood ·Mia Djulbegovic, Meredith Doherty, (unknown), Kan Chen, (unknown), P. Raymond Joslyn, (unknown), Joyce A. Mitchell, (unknown), Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam Waxman, Sandra P. Susanibar-Adaniya, (unknown), (unknown), Karen Glanz, Edward A. Stadtmauer	2
7	Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series 2023 ·Blood ·Margaret Stalker, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Sandra P. Susanibar-Adaniya, Mia Djulbegovic, Edward A. Stadtmauer, (unknown), Adam Waxman	1
8	Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy 2023 ·Blood ·Adam D. Cohen, Wei‐Ting Hwang, Sandra P. Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, (unknown), Chau Nguyen, (unknown), Marco Ruella, Michael C. Milone, Edward A. Stadtmauer	7
9	A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec) 2023 ·Blood ·Beatrice M. Razzo, (unknown), Sandra P. Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei‐Ting Hwang, Alfred L. Garfall	7
10	Radiation Therapy for Plasma Cell Disease of the Brain and Skull: Poor Palliation and Survival After Treatment for Central Nervous System Involvement 2021 ·Advances in Radiation Oncology ·(unknown), (unknown), (unknown), Russell Maxwell, Emily J. Anstadt, Adam Waxman, Joshua Jones, John P. Plastaras, Ima Paydar	2
11	AA amyloidosis associated with Castleman disease 2020 ·Medicine ·(unknown), Adam Waxman, Gabriel C. Caponetti, David C. Fajgenbaum, Brendan M. Weiss	7
12	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma 2019 ·Blood Advances ·Alfred L. Garfall, (unknown), Adam D. Cohen, Wei‐Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst	148
13	Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study 2018 ·Gastroenterology ·Ravy K. Vajravelu, Ronac Mamtani, Frank I. Scott, Adam Waxman, James D. Lewis	24
14	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 2018 ·Blood ·(unknown), Alfred L. Garfall, Adam D. Cohen, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst	22
15	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) 2018 ·Blood ·Adam D. Cohen, J. Joseph Melenhorst, Alfred L. Garfall, Simon F. Lacey, Megan M. Davis, Dan T. Vogl, Lifeng Tian, Vanessa Gonzalez, (unknown), Anne Marie Nelson, Gabriela Plesa, Adam Waxman, Regina M. Young, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer, Michael C. Milone	10
16	Modeling the risk of progression in smoldering multiple myeloma. 2014 ·Journal of Clinical Oncology ·Adam Waxman, Rosemarie Mick, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Edward A. Stadtmauer, Brendan M. Weiss	10
17	High prevalence of polyclonal hypergamma‐globulinemia in adult males in Ghana, Africa 2011 ·American Journal of Hematology ·Francis K. Buadi, Ann W. Hsing, Jerry A. Katzmann, Ruth M. Pfeiffer, Adam Waxman, Edward D. Yeboah, Richard Biritwum, Yao Tettey, Andrew A. Adjei, Lisa W. Chu, Angelo M. De Marzo, George J. Netto, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Ola Landgren	13
18	Multiple Myeloma Precursor Disease 2010 ·JAMA ·Ola Landgren, Adam Waxman	35
19	Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future 2010 ·Clinical Lymphoma Myeloma & Leukemia ·Adam Waxman, Michael Kuehl, Arun Balakumaran, Brendan M. Weiss, Ola Landgren	17
20	Racial disparities in incidence and outcome in multiple myeloma: a population-based study 2010 ·Blood ·Adam Waxman, Pamela J. Mink, Susan S. Devesa, William F. Anderson, Brendan M. Weiss, Sigurður Y. Kristinsson, Katherine A. McGlynn, Ola Landgren	275

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact